Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.58 |
| ▸ | PDE4A | P27815 | 4/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269812 | 0.90 | PDE4B (0.62) | MAPK1PARP15PARP10PARP2PDE4B | |
| SCHEMBL6940040 | 0.88 | TSHR (0.62) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL23047404 | 0.86 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6943737 | 0.83 | HSD17B2 (0.56) | MAPK1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7389578 | 0.82 | PDE4B (0.60) | PARP15PARP10PDE4BPDE4APDE4C | |
| SCHEMBL28034364 | 0.82 | MAPK1 (0.65) | MAPK1PARP15PARP10PARP2PDE4B | |
| SCHEMBL20463312 | 0.82 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15596058 | 0.82 | TSHR (0.66) | MAPK1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29670247 | 0.82 | TSHR (0.66) | MAPK1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12508471 | 0.81 | PDE4B (0.58) | PARP15PARP10PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | MAPK1 233/4885PARP15 2015/4885PARP10 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.